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dEffects of Oral Testosterone Treatment on Myocardial Perfusion
and Vascular Function in Men With Low Plasma Testosterone and
Coronary Heart Disease
Carolyn M. Webb, PhDa,b,*, Andrew G. Elkington, MDc, Mustafa M. Kraidly, MDa,b,
Niall Keenan, MRCPc, Dudley J. Pennell, MDc,d, and Peter Collins, MDa,b
Intracoronary testosterone infusions induce coronary vasodilatation and increase coronary
blood flow. Longer term testosterone supplementation favorably affected signs of myocar-
dial ischemia in men with low plasma testosterone and coronary heart disease. However,
the effects on myocardial perfusion are unknown. Effects of longer term testosterone
treatment on myocardial perfusion and vascular function were investigated in men with
CHD and low plasma testosterone. Twenty-two men (mean age 57  9 [SD] years) were
randomly assigned to oral testosterone undecanoate (TU; 80 mg twice daily) or placebo in
a crossover study design. After each 8-week period, subjects underwent at rest and ade-
nosine-stress first-pass myocardial perfusion cardiovascular magnetic resonance, pulse-
wave analysis, and endothelial function measurements using radial artery tonometry, blood
sampling, anthropomorphic measurements, and quality-of-life assessment. Although no
difference was found in global myocardial perfusion after TU compared with placebo,
myocardium supplied by unobstructed coronary arteries showed increased perfusion
(1.83  0.9 vs 1.52  0.65; p  0.037). TU decreased basal radial and aortic augmentation
indexes (p  0.03 and p  0.02, respectively), indicating decreased arterial stiffness, but
there was no effect on endothelial function. TU significantly decreased high-density li-
poprotein cholesterol and increased hip circumference, but had no effect on hemostatic
factors, quality of life, and angina symptoms. In conclusion, oral TU had selective and
modest enhancing effects on perfusion in myocardium supplied by unobstructed coronary
arteries, in line with previous intracoronary findings. The TU-related decrease in basal
arterial stiffness may partly explain previously shown effects of exogenous testosterone on
signs of exercise-induced myocardial ischemia.© 2008 Elsevier Inc.
(Am J Cardiol 2008;101:618–624)
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Open access under CC BY-NC-ND license.ith CHD.2,3 The aim of the present study was to investi-
ate the hypothesis that longer term oral testosterone unde-
anoate (TU) treatment beneficially affects myocardial per-
usion in men with established CHD and low testosterone.
econd, we investigated effects on vascular and endothelial
unction, selected metabolic risk factors for CHD, quality of
ife, and angina symptoms.
ethods
en aged 40 to 75 years with angiographically proven CHD
70% lesion in1 major coronary artery or major branch)
ere recruited from the outpatient departments, cardiac
atheterization lists, and hospital databases of the Royal
rompton and Harefield Hospitals, London, United King-
om. All patients had plasma testosterone 12 nmol/L and
ormal prostate-specific antigen (normal range 0 to 4 g/L).
xclusion criteria included myocardial infarction, coronary
ntervention, or thoracic or abdominal surgery in the previ-
us 3 months; hypertension; history of testosterone treat-
ent or similar hormone therapy; hemoglobin 16 g/dl;
ematocrit 50%; history of hormone-dependent cancer;
ermanent pacemaker; intolerance of confined spaces; or
articipation in another research study within the previous
0 days. The study complied with the Declaration of Hel-
www.AJConline.org
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619Coronary Artery Disease/Testosterone and Myocardial Perfusion in CHDinki, the protocol was approved by the local research ethics
ommittee, and all patients gave written informed consent.
The study used a randomized, placebo-controlled, cross-
ver design. After consenting to the study, a screening
lood sample was obtained to measure serum testosterone,
rostate-specific antigen, and full blood count. Patients ful-
lling the inclusion criteria then returned for a randomiza-
ion visit, at which anthropomorphic measurements were
btained, quality-of-life questionnaires were completed, and
tudy drug was dispensed (oral TU, 80 mg twice daily
Andriol Testocaps, Organon, Oss, The Netherlands] or
dentical placebo). After 8 weeks, an evaluation visit was
onducted that included measurement of myocardial perfu-
ion, endothelial function, quality-of-life assessment, and
lood sampling for measurement of hormone, lipid, and
emostatic profiles. Patients then crossed over to the oppo-
ite treatment and returned for identical repeated testing
fter an additional 8 weeks at the same time of day as the
rst evaluation visit. Patients completed a symptom diary
hroughout the study.
Patients were permitted to use current antianginal ther-
py throughout the randomized treatment period, but
topped vasoactive therapy (including statins) for 1 week
efore each evaluation visit. Sublingual glyceryl trinitrate
as permitted for treatment of anginal attacks during this
ime. However, if used on the day of the evaluation visit, it
as rescheduled. Patients fasted for6 hours, and caffeine-
ontaining beverages were prohibited for 12 hours before
ach evaluation visit.
All cardiovascular magnetic resonance (CMR) studies
ere performed on a 1.5-Tesla scanner (Siemens Sonata,
iemens, Germany) with a 4-channel body-array coil. For
ach study, first-pass myocardial perfusion at rest and with
denosine stress was assessed. A high-resolution saturation-
ecovery fast low-angle shot sequence was used (field of
iew read 320 to 400 mm, field of view phase 75% to 100%
f the field of view read, acquired voxel size 1.3 to 1.6 
.3 to 1.6, slice thickness 10 mm, flip angle 10°, acquisition
uration 295 ms, echo time 1.11 ms, and time from satura-
ion pulse to beginning of imaging 63 ms). Gadolinium-
iethylenetriaminepentaacetic acid was injected as a bolus
t 7 ml/s using a power injector (Medrad, Cambridgeshire,
nited Kingdom) through an 18 G intravenous cannula.
mages were acquired over 50 cardiac cycles, and patients
ere asked to breath-hold in end-expiration for as long as
as comfortable. One midventricular short-axis slice, repre-
entative of the whole ventricle, was acquired during each
ardiac cycle in diastole. The stress study was performed 20
inutes after the study at rest. Adenosine was infused for 4
inutes at 140 g/kg/min before stress images were acquired.
n the second visit, the short-axis slice planned to be imaged
as compared with the short-axis slice from the first visit to
nsure an equivalent slice was studied.
Because studies were analyzed quantitatively, a dual-
olus protocol was used.4,5 For both studies at rest and with
tress, patients received a low-dose (0.01 mmol/kg at 0.05
ol/L) bolus of gadolinium (Omniscan; Nycomed, Lidingö,
weden) approximately 2 minutes before a high-dose bolus
f gadolinium (0.1 mmol/kg at 0.5 mol/L). This allowed an
ccurate arterial input function and optimized signal in theyocardium. Blood pressure (BP) and heart rate were mon-
tored throughout each study.
On both visits, left ventricular (LV) volume, function,
nd mass measurements were acquired using breath-hold
egmented true fast imaging with steady-state precession
ines according to a standard protocol.6
Each study was analyzed by a blinded observer using
ustomized software (CMRtools; Cardiovascular Imaging
olutions, London, United Kingdom). For perfusion analy-
is, subendocardial and subepicardial myocardial borders
ere drawn and adjusted if necessary to compensate for
ardiac and respiratory motion. Arterial input function and
yocardial tissue response curves were corrected using
aseline subtraction, then assumed to be linearly propor-
ional to gadolinium concentration. An index of myocardial
erfusion (a unitless measure) was calculated at rest and at
tress from the respective first-pass myocardial signal inten-
ity-time curves using Fermi deconvolution.7 Myocardial
erfusion index (the ratio between stress and rest myocar-
ial perfusion) was calculated using model-based deconvo-
ution using the Fermi function. Each CMR image was
ivided into 4 (anterior, lateral, inferior, and septum), and
reas of myocardium supplied by coronary arteries with and
ithout significant (70% lesion) angiographically docu-
ented coronary stenosis were analyzed separately. LV
ass, end-diastolic and end-systolic volumes, and ejection
raction were determined using standard manual contouring
echniques.
able 1
atient characteristics (n  25)
ariable
ge (yrs) 57  8 (36–67)
o. significantly diseased major coronary arteries
1 6 (24%)
2 9 (36%)
3 10 (40%)
oronary intervention
Percutaneous coronary intervention 17 (68%)
Coronary artery bypass surgery 10 (40%)
ime since intervention (yrs)
Percutaneous coronary intervention 3  3 (0.4–11)
Coronary artery bypass surgery 4  4 (0.4–12)
yocardial infarction 14 (56%)
ime since myocardial infarction (yrs) 5  6 (0.4–17)
iabetes 3 (12%)
moking history
Current 2 (8%)
Ex 17 (68%)
Never 6 (24%)
tatin use 25 (100%)
ystolic BP (mm Hg) 132  20
iastolic BP (mm Hg) 76  12
eart rate (beats/min) 60  8
eight (kg) 91.5  13
aist-hip ratio 1.01  0.06
ody mass index (kg/m2) 30.5  3.5
ody surface area (m2) 2.9  3.7
otal testosterone (nmol/L) 9.4  2
rostate-specific antigen (g/L) 0.88  0.36
Values expressed as mean  SD (range) or number (percent).Peripheral pressure waveforms were recorded from the
r
C
m
t
H
K
a
p
f
u
c
A
p
p
s
d
p
s
s
v
S
h
d
l
M
u
a
b
K
B
K
l
C
t
w
8
o
c
d
g
e
t
t
1
r
l
r
i
e
r
f
t
s
w
o
r
w
i
D
c
d
a
F
l
F
(
a
d
S
T
H
V
T
F
B
D
S
1
F
L
620 The American Journal of Cardiology (www.AJConline.org)ight radial artery using applanation tonometry (Sphgmo-
or PX, version 6.31; AtCor, Sydney, Australia). BP was
easured noninvasively every 5 minutes throughout the
onometry study on the contralateral arm (Dinamap, GE
ealthcare, Chalfont St. Giles, Buckinghamshire, United
ingdom). Immediately after each BP measurement, radial
rtery pulse recordings were acquired with an averaged
eripheral waveform generated from 20 sequential wave-
orms. Corresponding central waveforms were generated
sing an online validated transfer function to determine
entral augmentation index, central pressure, and heart rate.
ugmentation index was calculated as the ratio of pulse
ressure at the second systolic arterial pressure waveform
eak to that of the first systolic peak and is a measure of arterial
tiffness. Patients underwent measurement of endothelium-
ependent and -independent responses using radial artery ap-
lanation tonometry before and after salbutamol (400 g) and
ublingual glyceryl trinitrate (250 g) as previously de-
cribed.8
Different aspects of quality of life were measured using
alidated questionnaires: the 36-Item Short Form Health
urvey questionnaire, which measures general health (a
igh score indicates better functioning or more pain)9; Car-
iac Health Profile, which measures cardiac well-being (a
ow score indicates a positive response10); and the Aging
ale Symptom Scale.11
Testosterone, 17-estradiol, sex hormone–binding glob-
lin, follicular-stimulating hormone, luteinizing hormone,
nd insulin were measured using radioimmunoassay (Ab-
ott IMX System; Abbott Diagnostics, Berkshire, United
ingdom), and glucose was measured using a standard
eckman Delta analyzer (Beckman Coulter UK Ltd, United
ingdom). Total cholesterol, high-density lipoprotein cho-
esterol, and triglycerides were measured using a Beckman
X7 analyzer. Low-density lipoprotein cholesterol was es-
imated using the formula of Friedewald. Full blood count
as measured using a standard technique with a Technicon
*1 analyzer (Bayer Technicon, United Kingdom). Fibrin-
gen and factor VII were measured using an automated
oagulometer (Instrumentation Laboratory, United King-
om), and plasminogen activator inhibitor-1, using chromo-
enic substrate assays.
Sample-size calculation was determined by the primary
able 2
ormone levels
ariable Basel
otal testosterone (nmol/L) 9.4 
ree testosterone (nmol/L) 0.23 
(%) 2.3 
ioavailable testosterone (nmol/L) 5.2 
(%) 52 
ihydrotestosterone (nmol/L) 1.18 
ex hormone–binding globulin (nmol/L) 29 
7-Estradiol (pmol/L) 123 
ollicular-stimulating hormone (IU/L) 5.9 
uteinizing hormone (IU/L) 3.9 
Values expressed as mean  SD.
* p 0.01 compared with placebo.nd point of myocardial perfusion. Our intracoronary tes- oosterone study showed an increase in blood flow to testos-
erone of approximately 10% to 15%.2 A mean difference of
5% in myocardial perfusion index with an SD of 0.5
equires 22 patients, with assumptions of a 5% significance
evel, 80% power to detect a difference between groups, and
andomization to the 2 groups in equal proportions. Allow-
ng for a 20% drop-out rate, 28 patients were required for
nrollment.
First, the size of the period-by-treatment interaction (car-
yover effect) was examined, and no carryover effect was
ound for any variable. Second, the difference between
reatment groups was analyzed by subtracting results of the
econd period from results from the first period, and a t test
as performed to compare these differences. An advantage
f this method compared with a paired t test is that it
emoves the effect of period from the analysis. When data
ere not normally distributed, analysis was performed us-
ng Mann-Whitney test. Significance was set at p 0.05.
ata are presented as mean  SD or mean difference (95%
onfidence interval).
For myocardial perfusion data, each CMR image was
ivided into 4 (as described). Because this violates the
ssumption of independence, data were analyzed in 2 ways.
irst, a t test was used (which assumes independence), then
inear regression with robust SEs to allow for repeated
igure 1. Bar graph shows mean myocardial perfusion index for placebo
black bars) and TU (hatched bars) for myocardial regions associated with
ngiographically documented significant coronary atheroma or perfusion
efect on preenrollment thallium scan and remaining “normal” regions.
ubendo  subendocardial; subepi  subepicardial.
Oral TU Placebo
10.2  3.9 10.4  2.4
0.27  0.1 0.25  0.06
2.7  0.4* 2.4  0.4
6.3  2.5 5.6  1.4
62  10* 54  10
2.2  1* 1.1  0.3
18.6  7.7* 25.3  10.8
141  64 176  102
4.2  1.6* 5.8  1.8
2.1  1.1* 3.8  1.5ine
2
0.06
0.5
1.6
12
0.33
17
75
2
2bservations from the same subjects.
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621Coronary Artery Disease/Testosterone and Myocardial Perfusion in CHDesults
pproximately 4,000 patients were contacted by post, and
0% of patients expressed interest in participating in the
tudy. Of these, approximately 80% were excluded because
f hypertension. One hundred nine patients attended for a
onsent and screening appointment. Half those screened had
estosterone greater than the inclusion criteria.
Twenty-eight patients were enrolled in the study, and 23
ompleted the protocol. Two patients were randomly as-
igned, but withdrew consent before taking the study drug
1 moved away and 1 repeatedly did not attend the random-
zation visit), and 1 patient was withdrawn after a few days
n study medication (TU) subsequent to hospitalization for
suspected stroke. One patient withdrew consent after the
rst treatment phase (placebo) because of depression, and 1
atient withdrew for personal reasons. Characteristics of the
5 patients who had at least 1 evaluation visit are listed in
able 1. Although not actively questioned about symptoms
f hypogonadism, 1 patient was known to have previously
sed testosterone treatment (stopped 3 months before ran-
omization). In addition, prerandomization Aging Male
ymptom Scale scores indicated that 22 patients (88%) had
oderate or severe impairment of sexual function. This
core was not changed by either testosterone or placebo.
Hormone levels are listed in Table 2. TU did not signif-
cantly change serum total testosterone or 17-estradiol;
owever, percentages of free and bioavailable testosterone
nd dihydrotestosterone levels increased (all p 0.001).
onversely, TU treatment was associated with a significant
ecrease in sex hormone–binding globulin, follicular-stim-
lating hormone, and luteinizing hormone (all p 0.001).
Twenty-two patients had assessable CMR data for both
valuation visits. Global myocardial perfusion was not sig-
ificantly different between treatments transmurally (1.8 
.7 vs 1.6  0.7, TU vs placebo; p  0.28) or in the
ubendocardium (1.8  0.7 vs 1.5  0.6, TU vs placebo;
 0.17) or subepicardium (1.8  0.7 vs 1.6  0.7, TU vs
lacebo; p  0.33). When analyzed by segments, no sig-
ificant difference in perfusion was shown in the subendo-
ardium (1.83  0.92 vs 1.54  0.88, TU vs placebo, p 
.2) or subepicardium (1.86  0.83 vs 1.65  0.89, TU vs
igure 2. Bar graph shows radial augmentation index at baseline, 20 minu
lacebo (black bars) and TU (hatched bars).lacebo, p  0.54) after adjustment for repeated measures. powever, myocardial segments supplied by coronary arter-
es without significant obstruction showed significant im-
rovement in the myocardial perfusion index of the suben-
ocardium (1.83  0.9 vs 1.52  0.65, TU vs placebo, p 
.037; Figure 1) and borderline improvement in the subepi-
ardium (1.85  0.82 vs 1.59  0.69, TU vs placebo, p 
.058; Figure 1) in patients administered TU versus pla-
ebo. Myocardial segments supplied by coronary arteries
ith significant coronary atherosclerosis showed no differ-
nce in myocardial perfusion indexes in the subendocar-
ium (1.83  0.94 vs 1.55  1.03, TU vs placebo respec-
ively; p  0.11) or subepicardium (1.86  0.84 vs 1.69 
.02, TU vs placebo; p 0.29). Adenosine did not decrease
eart rate or cause atrioventricular block in any patient.
Sixteen patients had LV data for both visits. LV ejection
raction was significantly higher after testosterone treatment
ompared with placebo (67  8% vs 65  8%; p  0.05).
owever, stroke volume (89  12 vs 88  14 ml; p 
.61), end-systolic volume (45  14 vs 47  14 ml; p 
.1), end-diastolic volume (135  19 vs 134  18 ml;
 0.97), and mass (170  33 vs 169  34 g; p  0.73)
ere not different.
Seventeen patients completed both endothelial function
ssessments. TU treatment was associated with significantly
ower baseline radial augmentation (p 0.03; Figure 2) and
ortic augmentation indexes (141  12 vs 147  9, TU vs
lacebo, respectively; p  0.02) compared with placebo,
ndicating a testosterone-induced decrease in basal arterial
tiffness. However, testosterone did not affect salbutamol-
nduced changes in radial augmentation indexes compared
ith placebo (p  0.48; Figure 2), signifying no effect on
ndothelium-dependent responses. Glyceryl trinitrate–
nduced decreases in radial augmentation indexes were sim-
lar after both treatments (p  0.15; Figure 2). Time to
eturn of reflected waves, an estimate of pulse-wave veloc-
ty,12 was prolonged after TU treatment compared with
lacebo (142.4  16.6 vs 137.2  9.3 ms; p  0.04).
rachial systolic BP was not altered throughout the tonom-
try study (148  16 vs 147  17 mm Hg, TU vs placebo;
 0.71). Similarly, there was no significant difference in
entral pulse pressure (52  10 vs 52  13 mm Hg, TU vs
r inhaled salbutamol, and 5 minutes after sublingual glyceryl trinitrate fortes aftelacebo, respectively; p  0.88) or heart rate at rest (62 
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622 The American Journal of Cardiology (www.AJConline.org)vs 60  7 beats/min, TU vs placebo, respectively; p 
.08).
TU treatment was associated with significantly lower
igh-density lipoprotein cholesterol and apolipoprotein-A1
nd higher high-density lipoprotein–low-density lipoprotein
atio compared with placebo (Table 3). Apolipoprotein-A1:
polipoprotein-B ratio decreased with borderline statistical
ignificance, and glucose and insulin were not different
etween treatments (Table 3).
There was no difference in plasminogen activator inhib-
tor-1, fibrinogen, or factor VII after treatment with TU or
lacebo (Table 3). Hematocrit slightly but significantly in-
reased after TU treatment (44.5  1.8% vs 43.5  1.9%,
U vs placebo, respectively; p  0.002). However, hemo-
lobin was not affected (15 0.6 vs 14.9 0.7 g/dl, TU vs
lacebo, respectively; p  0.22).
There was a statistically significant increase in hip cir-
umference after TU compared with placebo (108  6 vs
07  6 cm, respectively; p  0.03), but no difference in
ody weight (92  11 vs 92  13 kg; p  0.1), waist
ircumference (107  8 vs 108  10 cm; p  0.77),
aist-hip ratio (0.98  0.05 vs 1  0.06; p  0.14), body
urface area (2.1  0.2 vs 2.1  0.2 m2; p  0.08), or body
ass index (30.5  3.2 vs 30.7  3.6 kg/m2; p  0.9).
here was a trend toward a slight TU-induced increase in
eated systolic BP (141  17 vs 137  16 mm Hg; p 
.07); however, there was no difference in diastolic BP
83  8 vs 83  7 mm Hg; p  0.97) or heart rate (62 
vs 64  9 beats/min; p  0.37).
There was no significant difference between treatments
or any of the 36-Item Short Form Health Survey, Cardiac
ealth Profile, or Aging Male Symptom Scale measures
xamined and no difference in incidence of angina symp-
oms (2  5 vs 1  2 per 8-week treatment period, TU vs
lacebo, respectively). There were no other symptoms con-
able 3
etabolic and hemostatic variables
ariable
otal cholesterol (mmol/L)
(mg/dl)
igh-density lipoprotein cholesterol (mmol/L)
(mg/dl)
ow-density lipoprotein cholesterol (mmol/L)
(mg/dl)
igh-density–low-density lipoprotein cholesterol ratio
riglycerides (mmol/L)
ipoprotein(a) (mg/L)
polipoprotein A1 (g/L)
polipoprotein B (g/L)
polipoprotein A:Apolipoprotein B
lucose (mmol/L)
nsulin (mU/L)
lasminogen activator-1 (ng/ml)
ibrinogen (g/L)
actor VII (u/dl)
Values expressed as mean  SD.
* p 0.001 compared with placebo.
† p  0.01 compared with placebo.idered related to study drug. One patient who experienced salmost a depression” was administered placebo and did not
ross over to TU treatment.
iscussion
ur results show that 8 weeks of oral TU in men with CHD
nd low testosterone modestly increased myocardial perfu-
ion in myocardium supplied by unobstructed coronary ar-
eries, whereas perfusion in areas of myocardium supplied
y coronary arteries with significant coronary atheroma was
ot affected. To our knowledge, this is the first investigation
f blood flow effects of testosterone in territories associated
ith atherosclerotic coronary disease in humans. TU treat-
ent decreased basal peripheral and central arterial stiff-
ess, and concurrently, there was a comparative increase in
V ejection fraction. There was a null effect on overall
yocardial perfusion, global endothelial function, quality of
ife, and angina symptoms compared with placebo.
We report for the first time the effects of testosterone on
yocardial perfusion in myocardial territories supplied by
therosclerotic coronary arteries. A previous study showed
hat acute intracoronary testosterone induced coronary va-
odilation and increased coronary blood flow in unob-
tructed coronary arteries in patients with CHD in other
ajor epicardial coronary arteries, but flow responses were
ot measured in significantly diseased arteries.2 In line with
he intracoronary study, the present longer term study
howed testosterone-related enhancement of myocardial
lood flow in normally perfused regions of myocardium that
ay be mediated through effects on the epicardial coronary
rteries or/and microvasculature. Our previous short-term
ntracoronary testosterone study showed no effect on coro-
ary microvessels or coronary flow reserve.2 However, the
ifferent testosterone preparations and durations of treat-
ent used may have had differing effects. A previous study
f perfusion CMR in patients with cardiac syndrome X
eline Oral TU Placebo
 1.3 4.9  1.5 5.2  1.2
 51 191  58 203  47
 0.2 0.9  0.3* 1.1  0.2
 8 35  12 43  8
 1 3.1  1.5 3.1  1.1
 39 120  58 121  43
 0.77 5.3  1.3† 4.9  1
 0.68 2.1  1.7 2.1  1
done 276  338 323  362
done 1.2  0.3† 1.3  0.2
done 1 0.2 1  0.2
done 1.2  0.2 1.3  0.2
 1.3 5.9  1 5.9  0.9
done 9.7  4 10  4
 41 89  39 92  52
 0.7 3.2  0.7 3.2  0.8
 28 105  26 109  25Bas
4.3
168
0.99
40
2.5
97
4.37
1.68
Not
Not
Not
Not
5.9
Not
92
3.4
116howed subendocardial hypoperfusion in response to aden-
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623Coronary Artery Disease/Testosterone and Myocardial Perfusion in CHDsine, but no such effect was shown in the present study.13
t is perhaps surprising that we were unable to identify
nhanced perfusion in myocardial segments associated with
ignificant atherosclerosis because testosterone therapy in
he longer term has beneficial effects on signs of exercise-
nduced myocardial ischemia.3 TU-related decreases in
asal arterial stiffness imply that the mechanism involved in
his anti-ischemic effect may at least in part involve effects
n vascular tone (with no effect on BP or heart rate), thereby
ecreasing afterload. However, our myocardial perfusion
ata correspond with the null effect of testosterone treat-
ent on angina symptoms shown in both the present study
nd other reports.3
Puberty in males is associated with an increase in large-
essel arterial stiffness relative to prepubertal males, related
t least in part to changes in sex-steroid milieu.14 However,
recent longitudinal study in older men (mean age 68 years)
eported an independent inverse relation between endoge-
ous serum testosterone and arterial stiffness.15 Our results
rovide evidence that oral TU treatment has a beneficial
ffect on arterial stiffness in older men with testosterone at
r less than the lower limit of normal range. In light of
ecent research showing that arterial stiffness was a predic-
or of cardiovascular outcomes,16,17 our results may suggest
hat in the longer term, oral TU could potentially confer
ardiovascular benefit through its effects on arterial stiff-
ess. The endothelium did not appear to mediate effects of
ral TU on arterial stiffness or vascular tone in vivo in
umans, shown by the present study and others,18 although
nimal studies show that nitric oxide, prostacyclin, endo-
helium-derived hyperpolarizing factor, endothelin, and
hromboxane-A2 mediate testosterone-induced vascular ef-
ects.19,20 The lower augmentation index measured after TU
reatment could be caused by a combination of decreased
ave reflection (possibly from an effect on small vessels)
nd delayed wave reflection suggestive of lower pulse-wave
elocity from an effect on larger vessels (in the absence of
BP change).
Oral TU treatment resulted in a small but significant
ncrease in LV ejection fraction compared with placebo,
ith no associated difference in LV mass, stroke volume, or
nd-systolic or -diastolic volumes. This is interesting in
ight of a report of decreased LV ejection fraction in patients
ith low endogenous free testosterone21 and may be caused
y a direct action of TU on myocardial contractility.22
astration was associated with decreased cardiac perfor-
ance in male rats with slightly improved functioning in
astrated testosterone-replaced animals.23 These effects may
e explained by testosterone-induced actions on calcium-
yosin adenosine triphosphatase activity.24 However, data
re scarce and additional studies are needed, particularly
nvestigating the actions of physiologic testosterone re-
lacement on cardiac function in humans.
Plasma total testosterone levels did not increase after TU
reatment because TU is absorbed into the lymphatic system
ith newly formed cholymicrons, then subsequently ab-
orbed into blood from the intestine25 and rapidly converted
nto dihydrotestosterone.26 In this way, hepatic first pass is
voided. Dihydrotestosterone significantly increased and
ex hormone–binding globulin, luteinizing hormone, andollicular-stimulating hormone decreased after TU adminis-
ration.
The rationale for the 8-week treatment period was based
n our knowledge of the possible longer term mechanisms
f action of ovarian and related steroids on the vascular
ystem after long-term exposure.3,27 We therefore wished to
xpose patients to several weeks of therapy, and the avail-
ble data suggested a minimum period of 4 to 8 weeks. It is
ossible that testosterone therapy for longer periods may
how different results. Long-term testosterone treatment is
ikely to affect aspects of human cardiovascular physiology
hat were not measured in the present study, but that may
nfluence myocardial perfusion and vascular function. CMR
erfusion techniques are rapidly developing, and although
ewer methods may not change the overall results, they may
ive more comprehensive information, for example, single
ersus multiple slices. The anticipated changes in myocar-
ial perfusion and those shown were relatively small and it
ay be of interest to perform similar studies using different
erfusion techniques.
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